The primary objective of this study is to evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in delaying relapse of depressive symptoms (maintenance of effect) in participants with MDD.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
550
Oral tablet
Oral tablet
Time from Randomization to Relapse
Time frame: From randomization to the earliest of relapse or end-of study (up to approximately 32 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Neurocrine Clinical Site
Oceanside, California, United States
RECRUITINGNeurocrine Clinical Site
Orange, California, United States
RECRUITINGNeurocrine Clinical Site
San Jose, California, United States
RECRUITINGNeurocrine Clinical Site
New Haven, Connecticut, United States
RECRUITINGNeurocrine Clinical Site
Miami Gardens, Florida, United States
RECRUITINGNeurocrine Clinical Site
Orlando, Florida, United States
RECRUITINGNeurocrine Clinical Site
Palm Bay, Florida, United States
RECRUITINGNeurocrine Clinical Site
Tampa, Florida, United States
RECRUITINGNeurocrine Clinical Site
Iowa City, Iowa, United States
RECRUITINGNeurocrine Clinical Site
Marrero, Louisiana, United States
RECRUITING...and 50 more locations